Alzheimer Disease, CVA (Cerebrovascular Accident)
Conditions
Brief summary
Rivastigmine, an acetylcholinesterase inhibitor which has been approved by FDA & HSA, is authorized for use in the treatment of mild to moderate dementia of the Alzheimer's type. In this trial, the investigators will be studying the effectiveness of Rivastigmine in subjects with AD and cerebrovascular disease.
Interventions
DRUGRivastigmine
Sponsors
National Neuroscience Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Age between 50-85 years * Diagnosis of dementia of the Alzheimer's type according to the National Institute of Ageing-Alzheimer's Association Criteriah * MRI brain (with T2 or FLAIR sequences) performed within a 12 month period from time of recruitment demonstrating the presence of WMH of ≥2 on the Fazekas scale (Score range of 0-3 wherein a score of 1 indicates mild WMH, 2 indicates moderate WMH and 3 indicates severe WMH).i * Clinical Dementia Rating score of 1-2j * Mini-Mental State Examination (MMSE) scores of 12-26 inclusivek * English or Mandarin speaking, literate participants
Exclusion criteria
* Severe neurological, psychiatric or systemic disease which in the opinion of the clinician could interfere with trial assessments * The use of any investigational drugs, new psychotropic or dopaminergic agents, cholinesterase inhibitors or anti-cholinergic agents during the 4 weeks prior to recruitment * Known skin allergy or previous allergic reaction to Rivastigmine patch
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants with Demonstrated Benefit in Global and Cognitive Measures | 2 Years |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability | 2 Years |
Countries
Singapore
Outcome results
None listed